http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 03 Sep 2026 16:42:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++EAGLE+CAPITAL+GROWTH++++++For%3A+Sep+01++Filed+by%3A+SIMS+LUKE+E/27025681.html si-local-file:///var/storage/secattach/20260903/27025681.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++EAGLE+CAPITAL+GROWTH++++++For%3A+Sep+01++Filed+by%3A+SIMS+LUKE+E/27025681.html Thu, 03 Sep 2026 16:42:00 -0400 GRF http://www.streetinsider.com/Press+Releases/Green+Rise+Foods+Announces+Q2+Fiscal+2026+Financial+Results/27007169.html <p>Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - <b>Green Rise Foods Inc.</b> (TSXV: GRF) ("Green Rise" or the "Company") is pleased to release its interim condensed consolidated financial results for the three and six-month periods ended June 30, 2026.</p><p>The complete interim condensed consolidated financial statements and associated Management's Discussion and Analysis ("MD&#38;A") are available under the Company's profile at <u></u><a href="https://api.newsfilecorp.com/redirect/noa1OsjQee"><u>http://</u>www.sedarplus.ca</a>.</p><p><i><b>Selected Highlights for the three and six-month periods ended:</b></i></p><ul style="list-style-type: disc;"><li><p>Year-to-date fresh produce revenue of CDN $13.3 million for the six-month period ended June 30, 2026, versus $12.2 million for the comparative prior year period, representing an increase of 9% http://www.streetinsider.com/Press+Releases/Green+Rise+Foods+Announces+Q2+Fiscal+2026+Financial+Results/27007169.html Mon, 31 Aug 2026 19:19:00 -0400 GRF http://www.streetinsider.com/Newsfile/Green+Rise+Foods+Announces+Q2+Fiscal+2026+Financial+Results/27007169.html <p>Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - <b>Green Rise Foods Inc.</b> (TSXV: GRF) ("Green Rise" or the "Company") is pleased to release its interim condensed consolidated financial results for the three and six-month periods ended June 30, 2026.</p><p>The complete interim condensed consolidated financial statements and associated Management's Discussion and Analysis ("MD&#38;A") are available under the Company's profile at <u></u><a href="https://api.newsfilecorp.com/redirect/noa1OsjQee"><u>http://</u>www.sedarplus.ca</a>.</p><p><i><b>Selected Highlights for the three and six-month periods ended:</b></i></p><ul style="list-style-type: disc;"><li><p>Year-to-date fresh produce revenue of CDN $13.3 million for the six-month period ended June 30, 2026, versus $12.2 million for the comparative prior year period, representing an increase of 9% http://www.streetinsider.com/Newsfile/Green+Rise+Foods+Announces+Q2+Fiscal+2026+Financial+Results/27007169.html Mon, 31 Aug 2026 19:19:00 -0400 GRF http://www.streetinsider.com/SEC+Filings/Form++N-CSRS+++++EAGLE+CAPITAL+GROWTH++++++For%3A+Jun+30/26957111.html si-local-file:///var/storage/secattach/20260820/26957111.html http://www.streetinsider.com/SEC+Filings/Form++N-CSRS+++++EAGLE+CAPITAL+GROWTH++++++For%3A+Jun+30/26957111.html Thu, 20 Aug 2026 17:06:00 -0400 GRF O.03090273 http://www.streetinsider.com/SEC+Filings/Form++N-CSRS+++++EAGLE+CAPITAL+GROWTH++++++For%3A+Jun+30/26957111.html si-local-file:///var/storage/secattach/20260820/26957111.html http://www.streetinsider.com/SEC+Filings/Form++N-CSRS+++++EAGLE+CAPITAL+GROWTH++++++For%3A+Jun+30/26957111.html Thu, 20 Aug 2026 17:06:00 -0400 GRF O.03090273 http://www.streetinsider.com/SEC+Filings/Form++N-PX+++++++EAGLE+CAPITAL+GROWTH++++++For%3A+Aug+20/26956487.html si-local-file:///var/storage/secattach/20260820/26956487.html http://www.streetinsider.com/SEC+Filings/Form++N-PX+++++++EAGLE+CAPITAL+GROWTH++++++For%3A+Aug+20/26956487.html Thu, 20 Aug 2026 16:25:00 -0400 GRF O.03090273 http://www.streetinsider.com/SEC+Filings/Form++N-PX+++++++EAGLE+CAPITAL+GROWTH++++++For%3A+Aug+20/26956487.html si-local-file:///var/storage/secattach/20260820/26956487.html http://www.streetinsider.com/SEC+Filings/Form++N-PX+++++++EAGLE+CAPITAL+GROWTH++++++For%3A+Aug+20/26956487.html Thu, 20 Aug 2026 16:25:00 -0400 GRF O.03090273 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html <p>Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial evaluating Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).</p> <p>The last patient completed their final study visit, marking the "last patient, last visit" milestone for all 345 enrolled participants across 37 clinical sites in 16 countries. Topline results are expected by the end of 2026.</p> <p>SPARTA is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two weekly dose regimens of Prolastin-C — 60 mg/kg and 120 mg/kg — compared http://www.streetinsider.com/FDA/Grifols+completes+patient+follow-up+in+phase+3+alpha-1+lung+study/26894115.html Mon, 10 Aug 2026 07:01:39 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Press+Releases/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070 http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html <ul type="disc"><li style="text-align:justify;"><strong><em>Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin</em></strong><strong><em>®</em></strong><strong><em>-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema due to alpha-1 antitrypsin (AAT) deficiency (known as alpha-1)</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>The trial is the largest randomized, double-blind, placebo-controlled study on alpha-1 and augmentation therapy to-date and has the potential to provide clinical evidence on slowing progression of lung tissue loss in this patient group</em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>This milestone marks the completion of follow-up for all 345 participants enrolled across 37 sites in 16 countries </em></strong><br/><br/></li><li style="text-align:justify;"><strong><em>Top line results expected http://www.streetinsider.com/Globe+Newswire/Grifols+Announces+Last+Patient+Last+Visit+in+SPARTA%2C+its+Phase+3+Outcomes+Study+of+Prolastin%C2%AE-C+in+Patients+With+Emphysema+Due+to+Alpha-1+Antitrypsin+Deficiency/26894081.html Mon, 10 Aug 2026 07:00:00 -0400 A.50200972 GRF GRF-P GRFS O.00303353 O.00832070